CBIO Q1 2025 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-0.04

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$405,428

Balance Sheet

Total Assets

$6M

Total Liabilities

$3M

Stockholders' Equity

$3M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$14,620	+100.0%
Operating Income	-$2M	-$11M	+78.4%
Net Income	-$2M	-$11M	+78.2%